ReproCELL Incorporated

TSE:4978 Stock Report

Market Cap: JP¥9.4b

ReproCELL Balance Sheet Health

Financial Health criteria checks 6/6

ReproCELL has a total shareholder equity of ¥8.7B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥9.4B and ¥681.0M respectively.

Key information

0%

Debt to equity ratio

JP¥0

Debt

Interest coverage ration/a
CashJP¥5.17b
EquityJP¥8.74b
Total liabilitiesJP¥681.00m
Total assetsJP¥9.42b

Recent financial health updates

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Jul 17
Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Recent updates

ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Aug 05
ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Jul 17
Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

Feb 07
Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

Financial Position Analysis

Short Term Liabilities: 4978's short term assets (¥6.0B) exceed its short term liabilities (¥642.0M).

Long Term Liabilities: 4978's short term assets (¥6.0B) exceed its long term liabilities (¥39.0M).

Debt to Equity History and Analysis

Debt Level: 4978 is debt free.

Reducing Debt: 4978 has no debt compared to 5 years ago when its debt to equity ratio was 1.2%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4978 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4978 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 19.9% each year

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:41
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ReproCELL Incorporated is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Akinori UedaGoldman Sachs